Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences, Inc., headquartered in Menlo Park, California, is a prominent medical device company dedicated to innovating and commercializing cutting-edge technologies for the treatment of prevalent eye diseases. The company operates through two main segments: Surgical Glaucoma and Dry Eye.
In the Surgical Glaucoma segment, Sight Sciences offers the OMNI Surgical System. This versatile device allows for both canaloplasty and trabeculotomy with a single corneal incision, aimed at reducing intraocular pressure in adults with primary open-angle glaucoma. The efficacy of OMNI has been demonstrated in multiple clinical trials, showing favorable outcomes in lowering intraocular pressure across various stages of glaucoma.
In the Dry Eye segment, the TearCare System is available for ophthalmologists and optometrists. This system helps manage dry eye disease through a single interventional eyelid procedure, providing significant improvements in the signs and symptoms of the condition over time.
Recent clinical trials have highlighted the effectiveness of these devices. For example, the GEMINI Study demonstrated successful results using OMNI combined with cataract surgery, and the SAHARA trial confirmed the benefits of TearCare compared to traditional treatments.
Financially, Sight Sciences derives key revenue from its Surgical Glaucoma segment. The company has seen active customer engagement, as evidenced by the number of OMNI and SION system orders, as well as TearCare SmartLids sales.
For investors and stakeholders, Sight Sciences continues to be a compelling entity with its relentless focus on reimagining eye care through transformative technologies. The company's commitment to improving patient outcomes and expanding its market presence underscores its significance in the ophthalmic medical device industry.
Sight Sciences (Nasdaq: SGHT), a company dedicated to transforming eyecare through innovative technology, has announced its participation in the Bank of America Securities 2023 Health Care Conference in Las Vegas on May 10, 2023, at 3:40pm PT. The event will feature a fireside chat accessible via a live and archived webcast on the company’s investors page. Sight Sciences aims to enhance patient care with its products such as the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease. These minimally invasive solutions target the leading causes of eye issues, improving treatment outcomes over traditional methods.
Sight Sciences, Inc. (Nasdaq: SGHT), an innovative eyecare technology company, will report its financial results for Q1 2023 after market close on May 4, 2023. Management will host a conference call at 1:30 PM PT to discuss these results. Investors can access the live and archived webcast through the company’s website. Sight Sciences develops advanced solutions, including the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease, targeting prevalent eye diseases through non-invasive methods. These innovations aim to improve patient care and replace outdated treatments, positioning the company strongly in the eyecare market.
Sight Sciences Announces Surgical Glaucoma Investor Symposium
On April 13, 2023, Sight Sciences, Inc. (Nasdaq: SGHT) revealed plans for a Surgical Glaucoma Investor Symposium on May 5, 2023, in San Diego, CA, at 6:00 pm PT. The event will feature insights from leading glaucoma surgeons and remarks from the executive management team.
Attendance is limited and requires advance registration by April 21, 2023. A live webcast will be available on the investor relations website. Sight Sciences specializes in innovative eyecare solutions, focusing on minimally invasive treatments for glaucoma and other prevalent eye diseases.
Notable products include the OMNI® Surgical System for glaucoma management and the TearCare® System for dry eye disease.
Sight Sciences (Nasdaq: SGHT) has announced the appointment of Alison "Ali" Bauerlein as Chief Financial Officer and Treasurer, effective April 3, 2023. Bauerlein brings extensive experience from her previous role at Inogen, where she oversaw financial operations during significant growth phases. CEO Paul Badawi expressed confidence in Bauerlein's ability to support the company's strategic plan and financial infrastructure as it aims for profitable growth. Bauerlein's background in medtech and her previous success in scaling organizations are expected to positively influence Sight Sciences' trajectory in the eyecare technology sector.
Sight Sciences, Inc. (Nasdaq: SGHT) successfully defeated all four patent invalidity challenges from Alcon and Ivantis regarding its Hydrus® Microstent technology. The U.S. Patent Office denied the petitions, confirming the validity of Sight Sciences’ patents. This decision follows a lawsuit filed in 2021, seeking damages and injunctive relief against Ivantis for patent infringement. A jury trial is set for April 8, 2024, in Wilmington, Delaware. Sight Sciences boasts a robust patent portfolio covering innovative approaches to glaucoma treatment and aims to vigorously defend its intellectual property.
Sight Sciences, Inc. (Nasdaq: SGHT) reported strong financial results for Q4 and full-year 2022, with total revenue of $71.3 million, a 46% increase year-over-year. Q4 revenue reached $20.5 million, up 40% compared to Q4 2021. Surgical Glaucoma revenue rose to $18.8 million and Dry Eye revenue surged by 135% to $1.8 million. Operating expenses decreased sequentially to $33.9 million from Q3 2022. However, the net loss for Q4 was $16.9 million, while total operating expenses for 2022 increased by 56% year-over-year to $142.9 million. The company projects 2023 revenue between $89 million and $94 million, indicating expected growth of 25% to 32%.
Sight Sciences (Nasdaq: SGHT) has officially launched the Ergo-Series of the OMNI® Surgical System in the U.S., aimed at enhancing minimally invasive, implant-free glaucoma procedures.
The new features include:
- Improved Handle Ergonomics: Enhances precise control for surgeons.
- Simplified Viscoelastic Preparation: Removable luer connector for better clearance during surgery.
- New Cannula Tip Design: Enables gentler access to Schlemm's canal.
The Ergo-Series maintains the same therapeutic functionality as previous models, enabling effective treatment for patients with primary open-angle glaucoma.
FAQ
What is the current stock price of Sight Sciences (SGHT)?
What is the market cap of Sight Sciences (SGHT)?
What does Sight Sciences, Inc. do?
What products are offered by Sight Sciences in the Surgical Glaucoma segment?
What is the TearCare System?
Where is Sight Sciences, Inc. headquartered?
What were the findings of the GEMINI Study?
How does Sight Sciences contribute to treating dry eye disease?
What financial segment drives Sight Sciences' revenue?
Who can I contact for investor relations at Sight Sciences?
Are there any recent clinical highlights for Sight Sciences?
What trademarks does Sight Sciences hold?
